What is the outlook for Boston Scientific shares according to analysts?

Many analysts continue to maintain a bullish outlook on Boston Scientific shares, citing growth potential and upcoming clinical study data.

What potential catalyst is mentioned for Boston Scientific?

Upcoming clinical study data for the company's Watchman implant, expected in late March, is cited as a potential positive catalyst.

Home / Business and Economy / Boston Scientific Shares Plunge: Analysts Remain Bullish

Boston Scientific Shares Plunge: Analysts Remain Bullish

Q: Why did Boston Scientific's stock plunge recently?

Boston Scientific's stock experienced a significant selloff due to a disappointing profit forecast for 2026 and weaker-than-expected fourth-quarter growth in its Electrophysiology segment.

7 Feb

•

Summary

Boston Scientific shares dropped nearly 20% this week.
Analysts maintain bullish outlook despite stock's sharp decline.
Watchman implant clinical study data may serve as a catalyst.

Boston Scientific Shares Plunge: Analysts Remain Bullish

Boston Scientific Corp. experienced a significant stock selloff this week, with shares dropping nearly 20% following a disappointing profit forecast for 2026 and weaker-than-expected fourth-quarter growth in its Electrophysiology segment. This marks the stock's worst weekly decline since 2008, with Wednesday's 18% drop being its largest single-day loss in over 25 years.

Despite the sharp downturn, many analysts on Wall Street are maintaining their bullish stance. Prior to the earnings report, 35 out of 37 analysts tracked by Bloomberg had rated the stock as a 'buy.' Even after the results, the number of 'buy' ratings has increased, and the average price target remains substantially higher than the current trading price.